Sino-Therapeutics Pharmaceutical released its 2026 interim report. First-half operating revenue was 191 million yuan, down 13.0% year on year, and net profit attributable to the parent company was 29.7 million yuan, down 34.8% year on year. Second-quarter operating revenue was 96.61 million yuan, down 12.7% year on year, and net profit attributable to the parent company was 13.14 million yuan, down 47.6% year on year. The company said that performance declined due to the normalization of volume-based procurement in China's pharmaceutical industry and medical insurance cost controls, but it remains committed to R&D-driven growth and global expansion. Core products such as dapagliflozin metformin extended-release tablets grew significantly, enzalutamide tablets received marketing approval from the NMPA, and its internationalization strategy achieved results.
Sinotherapeutics Inc. AFirst-half net profit fell 34.8% year on year due to procurement normalization and medical insurance cost controls.
